• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

    10/16/24 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email

    Know Labs Retains the Stanbridge Group to Secure Automotive Joint Venture Partnerships

    Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive sensor technology, announced today that it has retained The Stanbridge Group to secure a strategic relationship with an automotive original equipment manufacturer to embed the Know Labs sensor technology in automobile steering wheels. In early preliminary tests, the Know Labs sensor demonstrated, in a laboratory setting, that it can non-invasively determine blood alcohol levels and the Company believes, in an automobile steering wheel, could prohibit an impaired individual from driving.

    This discovery occurred during the early development of the Company's non-invasive glucose monitoring technology. That lead to the filing in 2022 by Know Labs of a patent entitled, "Vehicle Interface Systems and Methods for Analyte-Based Control" on August 15, 2022. It was published on February 15, 2024, with publication number: US 2024/0050007 A1.

    Tucked within President Biden's 2021 Infrastructure Investment and Jobs Act is a mandate set to redefine the landscape of DUI prevention. By as early as 2026, all new vehicles sold within the country will need to be equipped with passive alcohol detection systems. The Know Labs platform directly addresses this issue.

    "While inventing and developing the Know Labs non-invasive diagnostic technology we have paid close attention to the many diverse fields of use in which our technology could be applied," said Ron Erickson, Know Labs' CEO. "Determining driver health and wellness is one of those fields of use. Our broad patent portfolio covers installing our sensor technology in an automobile steering wheel. We believe our sensor technology, embedded in steering wheels, can keep drunk drivers off the road and become the standard for the global auto industry. The Stanbridge Group is working to secure a joint venture partner for this exciting application of our platform technology while we continue the Company's core focus on non-invasive blood glucose monitoring."

    In 2022, drunk driving was responsible for 13,524 deaths in the United States according to the National Highway Traffic Safety Administration ("NHTSA"). As a consequence, NHTSA has initiated a proposed rule making process regarding Advanced Impaired Driving Prevention Technology.

    The Stanbridge Group, led by founder, Rick Stanbridge, has worked with senior leadership of automobile and original equipment automobile equipment manufacturers for many years. "Automobile and component manufacturers are all looking for a way to prevent impaired drivers from operating their vehicles," stated Rick Stanbridge. "The Know Labs sensor is a perfect solution for the problem manufacturers and the NHTSA are working to solve. We are thrilled to be working with Know Labs on this important project."

    For more information on Know Labs, visit www.knowlabs.co.

    About Know Labs, Inc.

    Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol "KNW." The Company's platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company's first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

    About The Stanbridge Group

    The Stanbridge Group conducts business in the United States and around the world. Their focus is on helping companies grow to the next level of expansion and profitability regardless of their geographic location. Most people forget that behind every large corporation there was once a small business. All the big corporate names here in the United States began as an entrepreneurial idea, with only a few employees, a market to fill, and the will and vision to grow. The Stanbridge Group has the tools and resources to take your business to the next level. For more information on The Stanbridge Group, visit www.thestanbridgegroup.com

    Safe Harbor Statement

    This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241016059079/en/

    Get the next $KNW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent partnership has Know Labs entered into?

      Know Labs has announced a partnership with The Stanbridge Group to integrate its non-invasive sensor technology into steering wheels of automobiles.

    • What is the primary purpose of the Know Labs sensor technology in automobiles?

      The Know Labs sensor technology is designed to detect blood alcohol levels non-invasively, potentially preventing drunk individuals from driving.

    • What upcoming regulation regarding DUI prevention is mentioned in the news?

      Under the Infrastructure Investment and Jobs Act, all new vehicles must be equipped with passive alcohol detection systems by 2026.

    • What key results have been observed during the testing of Know Labs' technology?

      The technology demonstrated promising results during preliminary tests for non-invasive blood alcohol level detection and is part of a broader patent portfolio for driver health monitoring.

    • What role is The Stanbridge Group playing in relation to Know Labs?

      The Stanbridge Group is tasked with securing joint venture partners for the automotive applications of Know Labs' technology while the company continues its focus on glucose monitoring.

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Jenkinson Linda

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:37:58 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 3 filed by new insider Jenkinson Linda

    3 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:30:18 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Chief Operating Officer Chapman Kirk

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:02:09 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Know Labs, Inc. Announces Adjournment of Special Meeting of Stockholders

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has adjourned its Special Meeting of Stockholders (the "Special Meeting") scheduled for July 24, 2025 in order to provide stockholders additional time to vote on all proposals described in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission on June 30, 2025. The Special Meeting will be reconvened at 1:30 p.m. Pacific Time on Thursday, July 31, 2025 at the following url: www.virtualshareholdermeeting.com/KNW2025SM. The record date for the reconvened Special

    7/24/25 5:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Reminds its Stockholders to Vote Ahead of the Special Meeting on July 24

    Know Labs, Inc. (NYSE:KNW) ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today issued a reminder to its stockholders to vote ahead of the Special Meeting of Stockholders (the "Special Meeting") to be held virtually on Thursday, July 24, 2025 at 1:30 p.m. pacific time. The methods for voting and submitting proxies are described in the previously distributed proxy materials for the Special Meeting. The Company's Board of Directors encourages any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote "For" each proposal, now. You may vote: over

    7/22/25 4:47:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

    6/6/25 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    SEC Filings

    View All

    SEC Form DEF 14A filed by Know Labs Inc.

    DEF 14A - USBC, Inc. (0001074828) (Filer)

    8/26/25 3:24:34 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form D filed by Know Labs Inc.

    D - USBC, Inc. (0001074828) (Filer)

    8/21/25 4:53:44 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - USBC, Inc. (0001074828) (Filer)

    8/15/25 8:31:15 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    6/3/24 2:11:39 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D filed by Know Labs Inc.

    SC 13D - KNOW LABS, INC. (0001074828) (Subject)

    10/25/23 7:27:11 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    10/19/23 6:32:18 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Financials

    Live finance-specific insights

    View All

    Know Labs, Inc. Reports Third Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

    8/14/23 4:15:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports Second Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

    5/15/23 4:05:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports First Quarter 2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

    2/14/23 4:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    View All

    Know Labs Appoints Chris Somogyi as President, International

    Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

    5/16/24 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Medical and Scientific Advisory Board

    New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

    12/14/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Board of Directors

    Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

    11/8/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials